Visfatin Serum Levels Predict Mortality in Critically Ill Patients

Figure 3

Visfatin is a biomarker for mortality in critically ill patients. (a) At the time of ICU admission, patients that died during the course of ICU treatment had significantly higher serum visfatin levels than survivors (). (b) Patients with high or low visfatin levels displayed different ICU mortalities by Kaplan-Meier survival curve analysis. (c) A similar observation was obtained when visfatin levels at ICU admission were compared between patients that died during the total observation period and survivors (). (d) High visfatin levels at ICU admission predicted the overall mortality during long-term follow-up in critically ill patients (Kaplan-Meier survival curve analysis for the optimal visfatin cutoff is displayed).

(a)

(b)

(c)

(d)